Flow Cytometry assay shows that Biotinylated Human PD-L1, Fc,Avitag,His Tag (Cat.No. PD1-H82F3) can bind to 293 cell overexpressing human PD-1. The concentration of PD-L1 used is 1 μg/mL (Routinely tested).
FACS analysis shows that the binding of Biotinylated Human PD-L1, Fc,Avitag,His Tag (Cat. No. PD1-H82F3) to 293 overexpressing PD-1 was inhibited by increasing concentration of neutralizing anti-PD-1 antibody. The concentration of PD-L1 used is 2 μg/mL. The IC50 is 0.64 μg/mL (Routinely tested).
Captured Mouse PD-1, Fc Tag (Cat. No. PD1-M5259) on Protein A Chip can bind Mouse PD-L1, His Tag (Cat. No. PD1-M5220) with an affinity constant of 2.16 μM as determined in SPR assay (Biacore T200) (Routinely tested).
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Avelumab | PF-06834635; MSB-0010718C | Approved | Merck Serono | Bavencio | United States | Carcinoma, Renal Cell | s:14:"Emd Serono Inc"; | 2017-03-23 | Lymphoma, Large B-Cell, Diffuse; Melanoma; Carcinoma, Hepatocellular; Leukemia, Lymphocytic, Chronic, B-Cell; Carcinoma, Non-Small-Cell Lung; Lymphoma, Non-Hodgkin; Fallopian Tube Neoplasms; Lymphoma; Esophageal Squamous Cell Carcinoma; Peritoneal Neoplasms; Colorectal Neoplasms; Oropharyngeal Neoplasms; Prostatic Neoplasms; Breast Neoplasms; Chordoma; Solid tumours; Papillomavirus Infections; Carcinoma, Ovarian Epithelial; Hodgkin Disease; Pancreatic Neoplasms; Triple Negative Breast Neoplasms; Glioblastoma; Carcinoma, Transitional Cell; Carcinoma; Stomach Neoplasms; Carcinoma, Renal Cell; Carcinoma, Merkel Cell; Squamous Cell Carcinoma of Head and Neck; Ovarian Neoplasms | Details |
| Atezolizumab | 52CMI0WC3Y (UNII code); RG-7446; MPDL-3280A; RO-5541267 | Approved | Genentech Inc | 泰圣奇, Tecentriq | United States | Melanoma | s:13:"Genentech Inc"; | 2016-05-18 | Fallopian Tube Neoplasms; Microsatellite Instability; Cholangiocarcinoma; Urologic Neoplasms; Colorectal Neoplasms; Peritoneal Neoplasms; Genital Neoplasms, Female; Thymoma; Neoplasms, Unknown Primary; Lymphoma, Non-Hodgkin; Lymphoma; Gallbladder Neoplasms; Esophageal Squamous Cell Carcinoma; Lung Neoplasms; Breast Neoplasms; Leukemia, Myeloid, Acute; Urogenital Neoplasms; Carcinoma, Squamous Cell; Uterine Neoplasms; Metastatic breast cancer; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Melanoma; Leukemia, Lymphocytic, Chronic, B-Cell; Uterine Cervical Neoplasms; Neoplasm Metastasis; Adenocarcinoma; Kidney Diseases; Head and Neck Neoplasms; Ovarian Neoplasms; Solid tumours; Kidney Neoplasms; Hematologic Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Stomach Neoplasms; Carcinoma, Merkel Cell; Esophageal Neoplasms; Triple Negative Breast Neoplasms; Small Cell Lung Carcinoma; Carcinoma, Transitional Cell; Liver Neoplasms; Papillomavirus Infections; Pancreatic Neoplasms; | Details |
| Durvalumab | MEDI-4736; 28X28X9-OKV (UNII code) | Approved | Medimmune Llc | 英飞凡, Imfinzi | Mainland China | Carcinoma, Non-Small-Cell Lung | s:18:"Astrazeneca Uk Ltd"; | 2018-02-16 | Lung Neoplasms; Prostatic Neoplasms, Castration-Resistant; Breast Neoplasms; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Prostatic Neoplasms; Peritoneal Neoplasms; Colorectal Neoplasms; Lymphoma, Non-Hodgkin; Endometrial Neoplasms; Digestive System Neoplasms; Esophageal Squamous Cell Carcinoma; Carcinoma, Pancreatic Ductal; Lymphoma, T-Cell, Cutaneous; Fallopian Tube Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Melanoma; Uterine Cervical Neoplasms; Carcinoma; Head and Neck Neoplasms; Biliary Tract Neoplasms; Hematologic Neoplasms; Ovarian Neoplasms; Kidney Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Carcinoma, Renal Cell; Solid tumours; Esophageal Neoplasms; Small Cell Lung Carcinoma; Carcinoma, Transitional Cell; Triple Negative Breast Neoplasms; Lymphoma, Large B-Cell, Diffuse; Pancreatic Neoplasms; Multiple Myeloma; Urinary Bladder Neoplasms | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| Durvalumab/Gefitinib | Phase 2 Clinical | Medimmune | Carcinoma, Non-Small-Cell Lung | Details | |
| IMC-001 | IMC-001; STI-3031; STI-A1015 | Phase 2 Clinical | Sorrento Therapeutics | Lymphoma, T-Cell, Peripheral; Biliary Tract Neoplasms; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Extranodal NK-T-Cell; Lymphoma, T-Cell; Neoplasm Metastasis; Gastrointestinal Neoplasms | Details |
| GNC-038 | GNC-038 | Phase 1 Clinical | Sichuan Baili Pharmaceutical Co Ltd | Solid tumours; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin | Details |
| Anti-CD19 CAR-T cells therapy (Tianjin Mycure Medical Technology) | Phase 1 Clinical | Tianjin Mycure Medical Technology Co Ltd | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
| CX-072 | CX-072 | Phase 2 Clinical | Cytomx Therapeutics | Triple Negative Breast Neoplasms; Breast Neoplasms; Lymphoma; Melanoma | Details |
| Human source and Fc engineered monoclonal antibody (MabSpace) | MSB-2311 | Phase 1 Clinical | Mabspace Biosciences | Neoplasms | Details |
| LY-3415244 | LY-3415244 | Phase 1 Clinical | Eli Lilly And Company | Neoplasms | Details |
| FS 118 | FS-118 | Phase 1 Clinical | Merck Serono, F-Star | Hematologic Neoplasms; Neoplasm Metastasis | Details |
| BMS-986189 | BMS-189; BMS-986189; PD-L1-Milla; BMS-986189-07 | Phase 1 Clinical | Bristol-Myers Squibb Company | Sepsis | Details |
| Cosibelimab | CK-301; TG-1501 | Phase 1 Clinical | Tg Therapeutics | Lymphoma | Details |
| FAZ-053 | LAE-005; FAZ-053 | Phase 1 Clinical | Novartis Pharma Ag | Triple Negative Breast Neoplasms; Chordoma | Details |
| KD-045 (Nanjing KAEDI Biotech) | KD-045 | Phase 1 Clinical | Nanjing Kaedi Biotechnology Co Ltd | Neoplasms | Details |
| KL-A167 | A-167; KL-A167; HBM-9167 | Phase 2 Clinical | Sichuan Kelun Botai Biomedicine Co Ltd | Lymphoma, B-Cell; Hodgkin Disease; Nasopharyngeal Carcinoma; Lymphoma, Extranodal NK-T-Cell; Lymphoma | Details |
| PD-L1/CTLA4 bispecific monoclonal antibody (Changhai Hospital) | Phase 2 Clinical | Changhai Hospital Of Shanghai | Pancreatic Neoplasms | Details | |
| BGB-A333 | BGB-A333 | Phase 2 Clinical | Beigene Ltd | Neoplasms | Details |
| 艾姆地芬 | Phase 1 Clinical | Tianjin Chase Sun Pharmaceutical Co Ltd, Chinese Academy Of Medical Sciences | Solid tumours | Details | |
| Chimeric antigen receptor T-cell therapy (Hunan Zhaotai Yongren Biotech) | Z-CTLs | Phase 1 Clinical | Hunan Zhaotai Yongren Biotech | Carcinoma, Non-Small-Cell Lung | Details |
| ALPN-202 | ALPN-202 | Phase 1 Clinical | Alpine Immune Sciences | Lymphoma | Details |
| Recombinant anti-PD-L1 human monoclonal antibody (Jiansu huaiyu) | Phase 1 Clinical | Jiangsu Huaiyu Pharmaceutical Co Ltd | Neoplasms | Details | |
| JS-003 | JS-003 | Shanghai Junshi Biosciences Co Ltd | Solid tumours | Details | |
| GS-4224 | GS-4224 | Phase 2 Clinical | Gilead Sciences Inc | Neoplasms; Hepatitis B | Details |
| INBRX-105 | INBRX-105 | Phase 1 Clinical | Inhibrx | Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Carcinoma, Transitional Cell; Hodgkin Disease; Esophageal adenocarcinoma; Lymphoma, Non-Hodgkin; Carcinoma, Non-Small-Cell Lung; Melanoma | Details |
| Anti PD-L1 monoclonal antibody (Biocad) | BCD-135 | Phase 1 Clinical | Biocad | Neoplasms | Details |
| ES101 | ES101 | Phase 1 Clinical | Inhibrx | Neoplasms | Details |
| IBI-322 | IBI-322 | Phase 1 Clinical | Innovent Biologics(Suzhou) Co Ltd | Solid tumours; Hematologic Neoplasms; Neoplasms | Details |
| c-Met/PD-L1 CAR-T cell (The Second Hospital of Nanjing Medical University) | Phase 1 Clinical | The Second Hospital Of Nanjing Medical University | Carcinoma, Hepatocellular | Details | |
| HLX-20 | HLX-20 | Phase 1 Clinical | Shanghai Henlius Biotech Co Ltd | Neoplasms | Details |
| FPT-155 | CD80-Fc; FPT-155 | Phase 1 Clinical | Five Prime Therapeutics | Neoplasms | Details |
| BMS-936559 | MDX-1105; BMS-936559 | Phase 3 Clinical | Bristol-Myers Squibb Company | Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Shock, Septic; Hodgkin Disease; Sepsis; Multiple Myeloma; Lymphoma, Non-Hodgkin; Carcinoma, Non-Small-Cell Lung; Melanoma | Details |
| RG-6084 | RG-6084 | Phase 1 Clinical | F. Hoffmann-La Roche Ltd | Hepatitis B | Details |
| MCLA-145 | MCLA-145 | Phase 1 Clinical | Incyte Corp, Merus | Neoplasms | Details |
| IBI318 | IBI-318; LY-3434172; LY3434172 | Phase 2 Clinical | Eli Lilly And Company, Innovent Biologics(Suzhou) Co Ltd | Small Cell Lung Carcinoma; Lymphoma, Extranodal NK-T-Cell; Carcinoma, Squamous Cell; Carcinoma, Hepatocellular | Details |
| IGV-001 | IGV-001 | Phase 2 Clinical | Thomas Jefferson University | Glioblastoma | Details |
| IBI-323 | IBI323; IBI-323 | Phase 1 Clinical | Innovent Biologics(Suzhou) Co Ltd | Solid tumours | Details |
| 18F-BMS-986192 | BMS-986192-[18F] | Clinical | Bristol-Myers Squibb Company | Neoplasms | Details |
| 89Zr-durvalumab | Phase 2 Clinical | Radboud University Nijmegen | Head and Neck Neoplasms | Details | |
| Pd-1-pik | Pd-1-pik | Phase 1 Clinical | Department Of Integrative Medicine, Huashan Hospital Of Fudan University, Shanghai, China | Glioblastoma | Details |
| LOR-S03 | CDX-527; LOR-A04; LOR-S01; LOR-S03 | Phase 1 Clinical | Celldex | Liver Neoplasms; Ovarian Neoplasms; Head and Neck Neoplasms; Solid tumours; Carcinoma, Renal Cell; Esophageal Neoplasms; Stomach Neoplasms; Microsatellite instability-high cancer; Urinary Bladder Neoplasms; Cholangiocarcinoma; Breast Neoplasms; Peritoneal Neoplasms; Colorectal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| Durvalumab/Selumetinib sulfate | Phase 1 Clinical | Astrazeneca Plc | Neoplasms | Details | |
| Dual-targeting HER2 and PD-L1 CAR-T Cell Therapy (Sichuan University) | Phase 1 Clinical | Sichuan University | Peritoneal Neoplasms | Details | |
| CA-170 | CA-170; AUPM-170 | Phase 2 Clinical | Aurigene | Solid tumours; Neoplasms | Details |
| GEN-1046 | GEN1046; PD-L1x4-1BB; DuoBody-PD-L1x4-1BB | Phase 2 Clinical | Biontech Se, Genmab | Solid tumours; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Transitional Cell; Triple Negative Breast Neoplasms; Endometrial Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms | Details |
| CK-301 | CK-301 | Phase 1 Clinical | Dana-Farber Cancer Institute | Head and Neck Neoplasms; Carcinoma, Renal Cell; Carcinoma, Merkel Cell; Carcinoma, Transitional Cell; Hodgkin Disease; Mesothelioma; Carcinoma, Squamous Cell; Lymphoma, Non-Hodgkin; Endometrial Neoplasms; Lung Neoplasms; Carcinoma, Small Cell; Carcinoma, Non-Small-Cell Lung; Melanoma | Details |
| ADG-104 | ADG-104; ADG104 | Phase 2 Clinical | Neoplasms | Details | |
| ND-021 | ND-021; NM21-1480 | Phase 2 Clinical | Numab Therapeutics Ag | Solid tumours; Neoplasms | Details |
| Recombinant human anti-PD-L1 monoclonal antibody (Guilin Sanjin) | Phase 2 Clinical | Guilin Sanjin Pharmaceutical Co Ltd, Adagene (Suzhou) Ltd, Dragonboat Biopharmaceutical, Baifan Biotechnology (Shanghai) Co Ltd | Carcinoma, Renal Cell; Urinary Bladder Neoplasms; Penile Neoplasms | Details | |
| Bintrafusp alfa | M-7824; GSK-4045154; MSB-0011359C | Phase 3 Clinical | Merck Serono | Biliary Tract Neoplasms; Solid tumours; Triple Negative Breast Neoplasms; Cholangiocarcinoma; Gallbladder Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms | Details |
| MAX-10181 | MAX-10181; MAX-1 | Phase 1 Clinical | Guangzhou Maxinovel Pharmaceiticals Co Ltd | Solid tumours | Details |
| PM-8001 | 6MW3111; PM-8001 | Phase 2 Clinical | Pumis Biotechnology (Zhuhai) Co Ltd | Solid tumours; Lung Neoplasms | Details |
| ABL-503 | ABL-503 | Abl Bio Inc | Details | ||
| Lodapolimab | LY-3300054 | Phase 1 Clinical | Eli Lilly And Company | Solid tumours; Skin Melanoma; Carcinoma, Renal Cell; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| TQB-2450 | APL-502; CBT-502; TQ-B2450 | Phase 3 Clinical | Cbt | Cholangiocarcinoma; Adenocarcinoma; Carcinoma, Hepatocellular; Melanoma; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Lymphoma; Fallopian Tube Neoplasms; Endometrial Neoplasms; Lung Neoplasms; Peritoneal Neoplasms; Solid tumours; Carcinoma, Ovarian Epithelial; Hodgkin Disease; Small Cell Lung Carcinoma; Triple Negative Breast Neoplasms; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Lymphoma, B-Cell; Liver Neoplasms; Head and Neck Neoplasms; Biliary Tract Neoplasms | Details |
| Recombinant anti-PD-L1 human monoclonal antibody (Hisun Pharm) | HS-636 | Phase 1 Clinical | Zhejiang Hisun Pharmaceutical Co Ltd | Neoplasms | Details |
| SHR-1316 | SHR-1316 | Phase 3 Clinical | Jiangsu Hengrui Medicine Co Ltd | Solid tumours; Small Cell Lung Carcinoma; Esophageal Squamous Cell Carcinoma; Carcinoma, Non-Small-Cell Lung | Details |
| Recombinant humanized PD-L1 monoclonal antibody (Taizhou Houde Aoke Technology) | LP-002 | Phase 2 Clinical | Taizhou Houde Aoke Technology Co Ltd | Solid tumours; Lymphoma, B-Cell; Small Cell Lung Carcinoma; Digestive System Neoplasms; Primary mediastinal B cell lymphoma; Carcinoma, Squamous Cell; Melanoma | Details |
| KN-046 | KN046; KN-046 | Phase 3 Clinical | Suzhou Alphamab Co Ltd | Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Triple Negative Breast Neoplasms; Breast Neoplasms; Thymus Neoplasms; Lymphoma; Esophageal Squamous Cell Carcinoma; Thymoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Gastrointestinal Neoplasms | Details |
| GR-1405 | GR-1405 | Phase 2 Clinical | Chongqing Zhixiang Jintai Biopharmaceutical Co Ltd, Zhixiang (Shanghai) Pharmaceutical Technology Co Ltd | Head and Neck Neoplasms; Solid tumours; Nasopharyngeal Carcinoma; Lymphoma | Details |
| SHR-1701 | SHR-1701 | Phase 2 Clinical | Jiangsu Hengrui Medicine Co Ltd | Solid tumours; Squamous Cell Carcinoma of Head and Neck; Pancreatic Neoplasms; Nasopharyngeal Carcinoma; Prostatic Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| Recombinant human anti-PD-L1 monoclonal antibody (Zhaoke Oncology) | ZKAB001; STI-A1014; STIA-1014 | Phase 3 Clinical | Zhaoke (Guangzhou) Oncology Pharmaceutical Ltd | Biliary Tract Neoplasms; Esophageal Neoplasms; Small Cell Lung Carcinoma; Carcinoma, Transitional Cell; Osteosarcoma; Bile Duct Neoplasms; Uterine Cervical Neoplasms | Details |
This web search service is supported by Google Inc.
A-Z
